This site is intended for Healthcare professionals only.
×

Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease


Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease
Rusan Pharma said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI). 
New Delhi: Drug maker Rusan Pharma recently said it has launched a drug to treat Parkinson’s disease. The drug — Aposan — is used to treat motor fluctuations in patients with Parkinson’s Disease which are not sufficiently controlled by oral medications currently available in the country.
The company said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI).

“The company has always put forward indigenously developed high technology advanced delivery products in the Indian market,” Rusan Pharma MD Kunal Saxena said in a statement.

The company wants to ensure that the treatment is affordable and accessible to all Parkinson’s disease patients, he added.

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: With input
0 comment(s) on Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted